VJOncology Podcast

Hosted by VJOncology

Technology

Website RSS feed

Episodes

237

Latest episode

Oct 2026

Language

EN-GB

About the show

The Video Journal of Oncology (VJOncology) podcast covers the latest oncology news from international experts across a view variety of solid tumors. Made for healthcare professionals and researchers, we are a global, independent, open-access platform. Listen to the latest news, including cutting-edge trial updates, controversies and opinion. If you enjoy the podcast, please leave us a rating and review! For more news visit www.vjoncology.com

Listen to episodes

60 recent

October 23, 2026Episode 24814 min

Personalizing prostate cancer management through genomic profiling

On this week’s episode of VJOncology podcasts, we explore advances in personalized approaches towards prostate cancer. Join Anis Hamid of Memorial Sloan Kettering Cancer Center, New York, NY, Daniel Keizman of Ichilov-Sourasky Medical Center, Tel-Aviv, Israel, Susan Halabi of Duke Cancer Institute, Durham, NC, and Andrew Armstrong of Duke University Medical Center, Durham, NC, as they discuss predictors of benefit for intensified therapy in metastatic hormone sensitive prostate cancer, a circulating tumor DNA (ctDNA)-based prognostic model in metastatic castration-resistant prostate cancer, and the association between tumor genetics, smoking and prostate cancer outcomes.

October 16, 2026Episode 24711 min

Reprogramming the tumor microenvironment: targeting acidity to unlock antitumor immunity

In this week’s VJOncology podcast, we are joined by Philippe Spiess of Moffitt Cancer Center, Tampa, FL, to explore the role of tumor acidity in cancer progression and immune evasion. Dr Spiess discusses how the acidic tumor microenvironment suppresses T-cell function, the potential of pH modulation to enhance antitumor immunity and improve responses to immunotherapy, and preclinical findings on tumor growth and survival. He also outlines an upcoming first-in-human trial investigating transdermal delivery of a therapy designed to modulate tumor pH, including its rationale, key safety and efficacy biomarkers, and potential role in combination with existing immunotherapies.

October 9, 2026Episode 24618 min

Breast Cancer Awareness Month: recent therapeutic and surgical advances

For this week’s VJOncology podcast, we mark Breast Cancer Awareness Month by bringing you the key updates in breast cancer. Join leading experts Zunairah Shah of Roswell Park Comprehensive Cancer Center, Buffalo, NY, Walter Weber of University Hospital Basel, Basel, Switzerland, Claudio Vernieri of Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, Yeon Hee Park of Samsung Medical Center, Seoul, South Korea, and Jennifer Ligibel of Dana-Farber Cancer Center, Boston, MA, as they discuss recent therapeutic and surgical advances. They explore data from the BWEL, PREPEC, DESTINY-Breast09, PALMARES-2, ASCENT-07 trials, as well as the link between GLP-1 receptor agonist therapy and breast cancer risk.

October 2, 2026Episode 24519 min

Liver Cancer Awareness Month: updates in treatment strategies and modalities

In this week’s VJOncology podcast, we mark Liver Cancer Awareness Month by exploring the latest advances in hepatocellular and hepatobiliary cancers. Join Ghassan Abou-Alfa of Memorial Sloan Kettering Cancer Center, New York, NY, Manon Allaire of Greater Paris University Hospitals, Paris, France, Stephen Lam Chan of The Chinese University of Hong Kong, Hong Kong, China, and Lorenza Rimassa of Humanitas University, Milan, Italy, as they discuss findings from the EMERALD-3 trial, challenges in selecting first-line therapies, the role of cirrhosis and artificial intelligence in patient management, evolving immunotherapy strategies, and emerging modalities including next-generation immune checkpoint inhibitors, antibody-drug conjugates, and cell therapies.

September 25, 2026Episode 24416 min

iwCAR-T 2026: advancing cellular therapies for solid tumors

This week on VJOncology podcasts, we bring you a roundtable discussion from iwCAR-T 2026 exploring novel cellular therapy technologies in solid tumors. Join Marco Davila of Roswell Park Comprehensive Cancer Center, Kedar Kirtane of Moffitt Cancer Center, Nathan Welty of Penn Medicine, Eric Smith of Dana Farber Cancer Center, Sebastian Kobold of Ludwig Maximilian University, and Yihan Zuo of Roswell Park Comprehensive Cancer Center, as they explore novel engineering strategies and how to overcome common issues with CAR T-cell therapy in solid tumors.

September 18, 2026Episode 24319 min

Lung cancer highlights from WCLC 2026

In this week’s VJOncology podcast, we had the opportunity to attend the 2026 World Conference on Lung Cancer (WCLC) in Seoul, South Korea, where we explored the latest advances across thoracic oncology. Join Tom Newsom-Davis of Chelsea and Westminster Hospital NHS Foundation Trust, London, UK, Giulia Pasello of Institute Oncology Veneto, Padua, Italy, Alexander Spira of Virginia Cancer Specialists and US Oncology, Fairfax, VA, Mark Jeng of Memorial Sloan Kettering Cancer Center, New York, NY, and Triparna Sen, Ohio State University, Columbus, OH, as they discuss the PAPILLON and REZILIENT 3 studies, perioperative treatment in mesothelioma, advances in small cell lung cancer, and more.

September 11, 2026Episode 24217 min

New frontiers in brain tumor treatment: from immunotherapy to precision medicine

In this week’s VJOncology podcast, we explore the latest developments in neuro-oncology, including emerging approaches in immunotherapy, PARP inhibition, and radioligand therapy. Join Nicholas Blondin and Sylvia Kurz of Yale University School of Medicine, New Haven, CT, Martin Hojgaard of Rigshospitalet, Copenhagen, Denmark, Tolga Tuncer of the University of Kansas Medical Center, Kansas, KC, and Dinu Stefan of François Baclese Cancer Center, Caen, France, as they discuss key ASCO findings, including the MAGMA and ROADS trials, lutetium-177 dotatate in meningioma, the molecular landscape of MTAP deletions, neoantigen-specific T-cell therapy for glioblastoma, and intermittent olaparib combined with radiotherapy and temozolomide in high-grade gliomas.

September 4, 2026Episode 24119 min

Gynecologic cancer awareness month: recent advances in treatment and diagnosis

In recognition of Gynecologic Cancer Awareness Month, this episode of VJOncology podcasts explores recent advances shaping the treatment and diagnosis of gynecologic cancer. Join leading experts Linda Mileshkin of Peter MacCallum Cancer Center, Melbourne, Australia, Martin Hojgaard of Rigshospitalet, Copenhagen, Denmark, Claudia Marchetti of Fondazione Policlinico Universitario Agostino Gemelli IRCSS, Rome, Italy, and Shailendra Dandge of the Society for Health Allied Research Education India, Hyderabad, India, as they discuss key developments. They cover new data for novel therapeutics including puxitatug samrotecan and EIK1003, the prognostic effect of neoadjuvant chemotherapy in ovarian cancer and a community health volunteer-led intervention to improve cervical cancer screening participation in low-resource settings.

August 28, 2026Episode 24017 min

Beyond lutetium: the next wave of radiopharmaceuticals in prostate cancer

In this week’s VJOncology podcast, we explore recent advances in therapeutic radiopharmaceuticals for metastatic castration-resistant prostate cancer, including emerging alternatives to lutetium-177. Join Jeremie Calais of University of California, Los Angeles, CA, Pedro Barata of Seidman Cancer Center, Cleveland, OH, and Enrique Gallardo of Parc Taulí University Hospital, Barcelona, Spain, as they discuss actinium-225-based PSMA-targeted radioligand therapies, findings from the CONVERGE-01, AcTION, and ProstACT Global trials, the expanding PSMA-targeted treatment landscape, and final overall survival results from PEACE-3.

August 14, 2026Episode 23918 min

Immunotherapy updates in head and neck cancer from ASCO 2026

On this week’s episode of VJOncology podcasts, we bring you head and neck cancer highlights in immuno-oncology from the 2026 ASCO Annual Conference. Join Barbara Burtness from the Yale School of Medicine, Hannah Kenny from Thomas Jefferson University Hospital, Ari Rosenberg from the University of Chicago, Nabil Saba from Emory University, and Kedar Kirtane from Moffitt Cancer Center as they discuss highlights from the meeting. They explore new data from key trials including OrigAMI-4, EV-202 and KEYNOTE-412, as well as emerging cellular therapies and checkpoint inhibitors.